Indicative timetable for de-listing from AIM
March 23 2009 - 12:44PM
UK Regulatory
TIDMTED
RNS Number : 3293P
Tepnel Life Sciences PLC
23 March 2009
Tepnel Life Sciences plc
23 March 2009
For Immediate Release
Recommended acquisition
of
Tepnel Life Sciences plc ("Tepnel")
by
Gen-Probe Incorporated ("Gen-Probe")
to be effected by means of a scheme of arrangement under Part 26 of the
Companies Act 2006
Indicative Timetable for De-listing from AIM
As laid out in the Scheme Document sent to Tepnel Shareholders on 21 February
2009 ("the Scheme Document"), for the information of Tepnel Shareholders, the
Tepnel Board details below an indicative timetable for the remaining steps to
implement the Scheme in accordance with its terms.
+--------------+----------------------+
| First | 3 April 2009 |
| Court | |
| Hearing | |
| (to | |
| sanction | |
| the | |
| Scheme) | |
| | |
+--------------+----------------------+
| Record | 6.00 p.m. on 6 April |
| Reduction | 2009 |
| Time | |
| | |
+--------------+----------------------+
| Suspension | 7.00 a.m. on 7 April |
| of listing | 2009 |
| and | |
| dealings | |
| in, and | |
| last time | |
| for the | |
| registration | |
| of transfers | |
| of, Tepnel | |
| Shares on | |
| AIM | |
+--------------+----------------------+
| Second | 7 April 2009 |
| Court | |
| Hearing | |
| (to | |
| confirm | |
| the | |
| Reduction | |
| of | |
| Capital) | |
| | |
+--------------+----------------------+
| Scheme | 6.00 p.m. on 7 April |
| Record | 2009 |
| Time | |
| | |
+--------------+----------------------+
| Effective | 8 April 2009 |
| Date of | |
| the | |
| Scheme | |
+--------------+----------------------+
| Cancellation | 7.00 a.m. on 8 April |
| of listing | 2009 |
| of Tepnel | |
| Shares on | |
| AIM | |
+--------------+----------------------+
| Latest | 14 days after the |
| date for | Effective Date |
| dispatch | |
| of | |
| cheques | |
| and | |
| settlement | |
| through | |
| CREST | |
+--------------+----------------------+
Any capitalised term used but not defined in this announcement has the same
meaning as is given to it in the Scheme Document.
For further information:
Tepnel Life Sciences plc
Ben Matzilevich, Chief Executive Officer
Michael Slater, Group Finance Director
Carol Smith, Group Marketing Communications Manager
Tel: 0161 946 2200
Capital MS&L
Mary Clark or Joanna Whineray
Tel: +44 20 7307 5330
Seymour Pierce Limited
Mark Percy
Tom Sheldon
Christopher Wren
Tel: +44 20 7107 8000
Seymour Pierce, which is authorised and regulated by the Financial Services
Authority, is acting exclusively for Tepnel and no one else in connection with
the Offer and will not be responsible to anyone other than Tepnel for providing
the protections afforded to clients of Seymour Pierce or for providing advice in
connection with the Offer or any matter referred to herein.
Merrill Lynch is acting for Gen-Probe in connection with the Offer and no one
else and will not be responsible to anyone other than Gen-Probe for providing
the protections afforded to clients of Merrill Lynch or for providing advice in
relation to the Offer, or any matter referred to herein.
Dealing Disclosure Requirements
Under the provisions of Rule 8.3 of the Code, if any person is, or becomes,
"interested" (directly or indirectly) in 1 per cent. or more of any class of
"relevant securities" of Tepnel, all "dealings" in any "relevant securities" of
Tepnel (including by means of an option in respect of, or a derivative
referenced to, any such "relevant securities") must be publicly disclosed by no
later than 3.30 p.m. (London time) on the Business Day following the date of the
relevant transaction. This requirement will continue until the date on which the
Scheme becomes effective or lapses or on which the "offer period" otherwise
ends. If two or more persons act together pursuant to an agreement or
understanding, whether formal or informal, to acquire an "interest" in "relevant
securities" of Tepnel, they will be deemed to be a single person for the purpose
of Rule 8.3.
Under the provisions of Rule 8.1 of the Code, all "dealings" in "relevant
securities" of Tepnel by Gen-Probe or Tepnel, or by any of their respective
"associates", must be disclosed by no later than 12.00 noon (London time) on the
Business Day following the date of the relevant transaction.
A disclosure table, giving details of the companies in whose "relevant
securities" "dealings" should be disclosed, and the number of such securities in
issue, can be found on the Panel's website at www.thetakeoverpanel.org.uk.
"Interests in securities" arise, in summary, when a person has long economic
exposure, whether conditional or absolute, to changes in the price of
securities. In particular, a person will be treated as having an "interest" by
virtue of the ownership or control of securities, or by virtue of any option in
respect of, or derivative referenced to, securities.
Terms in quotation marks are defined in the Code, which can also be found on the
Panel's website. If you are in any doubt as to whether or not you are required
to disclose a "dealing" under Rule 8, please contact an independent financial
adviser authorised under the Financial Services and Markets Act 2000, consult
the Panel's website at www.thetakeoverpanel.org.uk or contact the Panel on
telephone number +44 (0) 20 7638 0129; fax +44 (0) 20 7236 7013.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCILFSRVLIVFIA
Ted Baker (LSE:TED)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ted Baker (LSE:TED)
Historical Stock Chart
From Jul 2023 to Jul 2024
